Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $632,764.92 in Stock

Key Points

• Alnylam Pharmaceuticals EVP Kevin Joseph Fitzgerald sold 1,396 shares for a total of $632,764.92, reducing his ownership by 5.79% to 22,719 shares valued at approximately $10.3 million.
• The company's stock recently traded at $458.28, reflecting a market cap of $60.07 billion, while analysts have set a consensus price target of $405.33.
• Alnylam's latest quarterly earnings beat expectations, reporting $0.32 EPS against an anticipated loss of $0.54, accompanied by a 17.3% increase in revenue year-over-year.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 1,396 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $632,764.92. Following the completion of the sale, the executive vice president directly owned 22,719 shares in the company, valued at approximately $10,297,841.13. The trade was a 5.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $1.41 during trading hours on Tuesday, hitting $458.28. The company had a trading volume of 1,321,747 shares, compared to its average volume of 957,852. The firm has a market cap of $60.07 billion, a PE ratio of -185.54 and a beta of 0.25. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $462.88. The firm has a 50-day moving average of $348.15 and a 200 day moving average of $291.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. During the same period in the prior year, the firm earned ($0.13) EPS. The business's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on ALNY. Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research note on Monday, August 4th. JPMorgan Chase & Co. lifted their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $500.00 to $570.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Finally, Jefferies Financial Group upped their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $405.33.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. SVB Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $27,000. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $28,000. Whipplewood Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new position in Alnylam Pharmaceuticals during the second quarter worth $30,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.